Whitepaper: Phenotypic drug discovery with high content screening
Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.
List view / Grid view
Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.
Describing how a single nuclear stain can enable phenotypic profiling for new and additional perspectives on assays at no extra cost.
Water immersion lenses provide: brighter images from HCS samples; faster and gentler imaging; higher quality images from both 2D and 3D samples.
12 January 2018 | By MilliporeSigma
Expansion of hiPSCs as aggregates in stirred suspension...
12 January 2018 | By Merck
Expansion of hiPSCs as aggregates in stirred suspension...
In this application note, PerkinElmer demonstrates the ease and utility of the AlphaScreen® cAMP assay for detecting both agonist and antagonist-induced cAMP responses within cells.
In this application note, PerkinElmer demonstrates how LANCE® Ultra, a homogeneous assay format, can be used to quickly and accurately assess modulation of pSTAT3.
In this application note, PerkinElmer demonstrates the ease and utility of using LANCE® Ultra, a homogeneous assay format, for determining binding profiles of therapeutic monoclonal antibodies to FcγRs.
In this application note, PerkinElmer demonstrates the sensitivity, robust performance, and HTS suitability of the LANCE Ultra cytokine biomarker kits.
In this application note, PerkinElmer demonstrates the ease and utility of using AlphaLISA®, a homogeneous assay format, to screen for small molecular inhibitors of BET bromodomains.
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
In this paper, Thermo Fisher Scientific aim to assess the performance of Thermo Scientific Varioskan LUX when running NanoBRET.
In this application note, PerkinElmer demonstrate the utility of an AlphaLISA assay for screening biotherapeutic antibodies and compounds that block binding of human PD-1 and PD-L1.
Next generation sequencing sample preparation on the KingFisher platform...
An entirely new area of stem cell biology was introduced by Shinya Yamanaka in 2006 when he discovered that somatic cells could revert back to pluripotent-like cells, or induced pluripotent stem cells (iPSCs).